ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs SER 287 (Primary) ; Vancomycin
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms ECO-RESET
- Sponsors Seres Therapeutics
- 02 May 2019 According to a Seres Therapeutics media release, if this trial results are positive, the study could serve as one of two pivotal trials to enable a SER-287 Biologics License Application (BLA) submission.
- 02 May 2019 According to a Seres Therapeutics media release, the company expects to complete enrolment in this trial by mid-2020 and top-line data is expected in 3Q 2020.
- 28 Nov 2018 Status changed from planning to recruiting.